atenolol and simvastatin

atenolol has been researched along with simvastatin in 33 studies

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (3.03)18.2507
2000's12 (36.36)29.6817
2010's18 (54.55)24.3611
2020's2 (6.06)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ekins, S; Williams, AJ; Xu, JJ1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS1
Lee, TH1
Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV1
Ito, MK; Pieper, JA; Talbert, RL1
Diener, HC1
Kumar, V; Shah, RP; Singh, S1
Ang, PS; Su, DH; Tow, SL1
Sundermeyer, M; Veeraputhiran, M1
Afzal, R; Pais, P; Pogue, J; Sigamani, A; Xavier, D; Yusuf, S1
Afzal, R; Eikelboom, J; Gupta, R; Mohan, V; Pais, P; Sigamani, A; Teo, K; Thomas, N; Xavier, D; Yusuf, S1
Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T1
Bai, YM; Chou, YH; Liang, CS; Liou, YJ1
Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO1
Afzal, R; Gao, P; Pais, P; Sigamani, A; Teo, KK; Xavier, D; Yusuf, S1
Gugssa, SA; Johnston, JC1
Bautista, LE; Casas, JP; Chirinos, JA; Ferrante, D; Ferreccio, C; Herrera, VM; Medina-Lezama, J; Miranda, JJ; Oróstegui Arenas, M; Pérez, CM; Pichardo, R; Sánchez Abanto, JR; Schapochnik, N; Silva, E; Vera-Cala, LM1
Billot, L; Bompoint, S; Bots, ML; Cidambi, R; Field, J; Grobbee, DE; Patel, A; Poulter, N; Prabhakaran, D; Reddy, KS; Rodgers, A; Stanton, A; Thom, S1
Billot, L; Bompoint, S; Brown, A; Burch, C; Burke, H; Cass, A; Hayman, N; Hillis, GS; Jan, S; Molanus, B; Neal, B; Patel, A; Peiris, D; Rafter, N; Reid, CM; Rodgers, A; Shiel, L; Togni, S; Tonkin, A; Usherwood, T; Webster, R1
Arroll, B; Bramley, D; Bryant, L; Bullen, C; Crengle, S; Doughty, RN; Elley, CR; Harwood, M; Jackson, R; Milne, RJ; Parag, V; Rafter, N; Rodgers, A; Selak, V; Wadham, A1
Bots, ML; Grobbee, DE; Lafeber, M; Patel, A; Prabhakaran, D; Rodgers, A; Spiering, W; Stanton, A; Thom, S; Visseren, FL; Webster, R1
Cheruvu, HS; Devalapalli, MMR; Sampathi, S; Shivakumar, S; Veeravalli, VB; Yertha, T1
Bosch, J; Dans, AL; Gamra, H; Gao, P; Joseph, P; Lopez, PC; Lopez-Jaramillo, P; Pais, P; Santoso, A; Talukder, S; Teo, K; Tyrwhitt, J; Xavier, D; Yeates, K; Yusoff, K; Yusuf, S1
Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS; Serag, A1
Bosch, J; Christou, C; Dagenais, G; Dans, A; Gamra, H; Gao, P; Girish, P; Joseph, P; López-Jaramillo, P; McCready, T; Pais, P; Rocha, C; Santoso, A; Talukder, S; Teo, K; Tyrwhitt, J; Xavier, D; Xavier, F; Yeates, K; Yusoff, K; Yusuf, S1

Reviews

3 review(s) available for atenolol and simvastatin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:5

    Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Simvastatin; Stroke

2012
Syphilitic aortic aneurysm with spastic paraparesis: a novel presentation and review of the literature.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Aorta, Thoracic; Aortic Aneurysm, Thoracic; Atenolol; Disease Outbreaks; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Paraparesis, Spastic; Penicillins; Simvastatin; Spinal Cord Compression; Syphilis; Time Factors

2012

Trials

10 trial(s) available for atenolol and simvastatin

ArticleYear
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
    Nature clinical practice. Cardiovascular medicine, 2009, Volume: 6, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Capsules; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Research Design; Secondary Prevention; Simvastatin; Treatment Outcome

2009
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
    Lancet (London, England), 2009, Apr-18, Volume: 373, Issue:9672

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Risk Reduction Behavior; Simvastatin; Treatment Outcome

2009
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolol; Biological Availability; Capsules; Cardiovascular Diseases; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Simvastatin; Tandem Mass Spectrometry; Young Adult

2010
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
    Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4

    Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Capsules; Cardiovascular Diseases; Cholesterol, LDL; Creatinine; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; India; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Potassium; Ramipril; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome

2012
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
    JAMA, 2013, Sep-04, Volume: 310, Issue:9

    Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Female; Humans; Hydrochlorothiazide; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin; Treatment Outcome

2013
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    European journal of preventive cardiology, 2015, Volume: 22, Issue:7

    Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Australia; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol; Drug Combinations; Drugs, Generic; Female; General Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lisinopril; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Primary Prevention; Prospective Studies; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors; Tablets; Time Factors; Treatment Outcome

2015
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    BMJ (Clinical research ed.), 2014, May-27, Volume: 348

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; New Zealand; Primary Health Care; Regression Analysis; Risk Factors; Simvastatin; Young Adult

2014
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    European journal of preventive cardiology, 2017, Volume: 24, Issue:9

    Topics: Administration, Oral; Aged; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Drug Substitution; Europe; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome

2017
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
    American heart journal, 2018, Volume: 206

    Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Female; Global Health; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Primary Prevention; Ramipril; Retrospective Studies; Simvastatin

2018
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
    The New England journal of medicine, 2021, 01-21, Volume: 384, Issue:3

    Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Incidence; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin

2021

Other Studies

20 other study(ies) available for atenolol and simvastatin

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
    Bioorganic & medicinal chemistry, 2017, 11-01, Volume: 25, Issue:21

    Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles

2017
In the past 12 to 18 months, my level of anxiety has increased significantly. I have been on atenolol and simvastatin (Zocor) for the past couple of years. Is there anything in these drugs that could cause this anxiety?
    Harvard heart letter : from Harvard Medical School, 1998, Volume: 9, Issue:2

    Topics: Adrenergic beta-Antagonists; Anxiety; Atenolol; Humans; Simvastatin

1998
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
    Kardiologiia, 2003, Volume: 43, Issue:3

    Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Indapamide; Male; Metabolic Syndrome; Middle Aged; Perindopril; Pyrroles; Simvastatin; Treatment Outcome

2003
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jul-01, Volume: 60, Issue:13 Suppl 2

    Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Niacin; Obesity; Risk Factors; Simvastatin

2003
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
    MMW Fortschritte der Medizin, 2003, Volume: 145 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke

2003
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
    Journal of pharmaceutical and biomedical analysis, 2008, Jul-15, Volume: 47, Issue:3

    Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization

2008
Bilateral posterior ischemic optic neuropathy associated with use of sildenafil.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2008, Volume: 28, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Chinese Herbal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypotension; Male; Optic Nerve; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Retinal Artery; Risk Factors; Sildenafil Citrate; Simvastatin; Sulfones; Vision, Low

2008
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
    Clinical lung cancer, 2008, Volume: 9, Issue:4

    Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed

2008
Acute renal failure after paliperidone overdose: a case report.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:1

    Topics: Acidosis; Acute Kidney Injury; Adult; Anticholesteremic Agents; Antihypertensive Agents; Antipsychotic Agents; Atenolol; Blood Urea Nitrogen; Creatinine; Dose-Response Relationship, Drug; Drug Overdose; Drug Therapy, Combination; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Self Medication; Simvastatin

2012
A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
    Health affairs (Project Hope), 2013, Volume: 32, Issue:1

    Topics: Aged; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Developing Countries; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Latin America; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors

2013
Hansen solubility parameters for assay method optimization of simvastatin, ramipril, atenolol, hydrochlorothiazide and aspirin in human plasma using liquid chromatography with tandem mass spectrometry.
    Journal of separation science, 2017, Volume: 40, Issue:18

    Topics: Aspirin; Atenolol; Chromatography, Liquid; Humans; Hydrochlorothiazide; Ramipril; Reproducibility of Results; Simvastatin; Solubility; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2017
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2020, Sep-05, Volume: 238

    Topics: Algorithms; Aspirin; Atenolol; Capsules; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Least-Squares Analysis; Ramipril; Simvastatin; Spectrophotometry, Ultraviolet

2020